Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Fong · SciRah

Researcher profile · Semantic Scholar

C. Fong

Share profile

C. Fong — researcher profile on SciRah

h-index: 15
Works: 69
Citations: 1,574

Most-cited papers

BET inhibitor resistance emerges from leukaemia stem cells
C. Fong, O. Gilan, E. Lam, Alan F. Rubin +22 more
2015Nature519 citations Open access
Semantic Scholar
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia
Charles C. Bell, K. A. Fennell, Yih-Chih Chan, F. Rambow +32 more
2019Nature Communications167 citations Open access
Semantic Scholar
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chong Chyn Chua, A. Roberts, J. Reynolds, C. Fong +11 more
2020Journal of Clinical Oncology162 citations
Semantic Scholar
Functional interdependence of BRD4 and DOT1L in MLL leukemia
O. Gilan, E. Lam, Isabelle Becher, Dave Lugo +27 more
2016Nature Structural &Molecular Biology105 citations Open access
Semantic Scholar
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
Nadine Hein, Donald P. Cameron, K. Hannan, N. Nguyen +26 more
2017Blood87 citations Open access
Semantic Scholar
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia
I. Tiong, R. Dillon, A. Ivey, Tse-Chieh Teh +12 more
2020British Journal of Haematology83 citations Open access
Semantic Scholar
Epigenetics in the hematologic malignancies
C. Fong, J. Morison, M. Dawson
2014Haematologica78 citations Open access
Semantic Scholar
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.
P. Yeh, Michael Dickinson, Sarah Ftouni, Tane Hunter +10 more
2017Blood60 citations
Semantic Scholar
Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
Jacqueline S. Garcia, A. Wei, U. Borate, C. Fong +15 more
2020Blood47 citations Open access
Semantic Scholar
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome
A. Wei, Jacqueline S. Garcia, U. Borate, C. Fong +14 more
2019Blood46 citations Open access
Semantic Scholar
Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse
A. Lim, C. Curley, C. Fong, I. Bilmon +18 more
2018Internal medicine journal (Print)19 citations Open access
Semantic Scholar
Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study
E. Hawkes, G. Chong, Charmaine D. Smith, Sze T. Lee +15 more
202017 citations Open access
Semantic Scholar
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia.
S. Loo, N. Potter, A. Ivey, J. O'Nions +16 more
2024Blood15 citations Open access
Semantic Scholar
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
G. Garcia-Manero, Maciej Kaźmierczak, Agnieszka Wierzbowska, C. Fong +4 more
2024Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis15 citations
Semantic Scholar
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse
C. Fong, G. Grigoriadis, J. Hocking, J. Coutsouvelis +9 more
2013Leukemia and Lymphoma15 citations Open access
Semantic Scholar
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study
K. Manos, G. Chong, C. Keane, Sze T. Lee +16 more
2023Leukemia14 citations
Semantic Scholar
A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
A. Wei, C. Fong, P. Montesinos, M. Calbacho +12 more
2019Blood13 citations Open access
Semantic Scholar
A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
I. Tiong, D. Hiwase, E. Abro, A. Bajel +7 more
2021Blood11 citations Open access
Semantic Scholar
Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
Jacqueline S. Garcia, U. Platzbecker, O. Odenike, Shaun A. Fleming +9 more
2023Blood8 citations Open access
Semantic Scholar
BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-Risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study
D. Lavie, V. Ribrag, Michael Loschi, C. Yannakou +27 more
2023Blood8 citations Open access
Semantic Scholar
High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial
Chong Chyn Chua, S. Loo, J. Reynolds, I. Tiong +5 more
2022Blood7 citations Open access
Semantic Scholar
Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study
Chong Chyn Chua, J. Reynolds, J. Salmon, C. Fong +13 more
2019Blood7 citations
Semantic Scholar
Blinatumomab in de novo AYA ALL—Results of the Australasian Leukaemia and Lymphoma Group ALL09 “SUBLIME” study
Matthew Greenwood, Shane A Gangatharan, Michael Osborn, Ashley P Ng +22 more
2026HemaSphere6 citations
Semantic Scholar
MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
A. Wei, Jacqueline S. Garcia, U. Borate, C. Fong +14 more
20216 citations
Semantic Scholar
A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)
G. Garcia-Manero, M. Kaźmierczak, C. Fong, P. Montesinos +4 more
2019Blood6 citations Open access
Semantic Scholar
Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
G. Mannis, C. Abboud, N. Daver, G. Murthy +14 more
2025eJHaem5 citations Open access
Semantic Scholar
Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies
T. Kadia, Patricia Kropf, M. Leahy, C. Chua +17 more
2025Blood4 citations
Semantic Scholar
Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine
D. Hiwase, David M. Ross, David T. Yeung, Agnes S. M. Yong +6 more
2024Blood4 citations
Semantic Scholar
Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
J. Othman, I. Tiong, K. Mokretar, A. Ivey +24 more
2022Blood4 citations
Semantic Scholar
A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
D. Ross, A. Arbelaez, L. Chee, C. Fong +17 more
2021Blood4 citations Open access
Semantic Scholar
Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies.
M. Leahy, Shaun A. Fleming, Patricia Kropf, Chua C. Chong +16 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia
D. Hiwase, David M. Ross, S. Lane, C. Thompson-Peach +5 more
2023Blood3 citations
Semantic Scholar
BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
R. Ayala, N. López, Adi Shacham Abulafia, M. Alwan +20 more
2022Blood3 citations Open access
Semantic Scholar
Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)
I. Tiong, R. Dillon, A. Ivey, Tse-Chieh Teh +16 more
2019Blood3 citations Open access
Semantic Scholar
Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals
Chong Chyn Chua, A. Grigg, Jasmine Singh, Mark Droogleever +7 more
2019Leukemia and Lymphoma3 citations
Semantic Scholar
A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).
G. Garcia-Manero, C. Fong, A. Venditti, S. Mappa +2 more
20183 citations
Semantic Scholar
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.
C. Fong, A. Wei, M. Frattini, Meagan A. Jacoby +16 more
20183 citations
Semantic Scholar
Parvovirus B19–induced pure red cell aplasia in a heart transplant recipient.
C. Fong, Z. Kaplan
2012Blood3 citations Open access
Semantic Scholar
Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study
M. Greenwood, Shane A Gangatharan, M. Osborn, Ashley P Ng +16 more
2022Blood2 citations Open access
Semantic Scholar
AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
E. Hawkes, K. Manos, Charmaine Smith, J. Hawking +14 more
2019Blood2 citations Open access
Semantic Scholar
Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 “Sublime” Study
O. Pitiyarachchi, Madeleine T King, Shane A Gangatharan, Michael Osborn +18 more
2024Blood1 citations
Semantic Scholar
CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
Kelly Lim, M. Kutyna, W. Kan, Angel F. Lopez +9 more
2024Blood1 citations
Semantic Scholar
MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study
Rosa Ayala, N. López, A. Abulafia, M. Alwan +24 more
2023Clinical Lymphoma, Myeloma & Leukemia1 citations Open access
Semantic Scholar
Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes
I. Tiong, A. Ivey, K. Fielding, C. Fong +1 more
2022Blood1 citations
Semantic Scholar
Outcomes of non‐myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission
Phillip C Nguyen, K. Manos, C. Fong, A. Schwarer +4 more
2021Internal medicine journal (Print)1 citations
Semantic Scholar
MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
Jacqueline S. Garcia, A. Wei, U. Borate, C. Fong +17 more
20201 citations
Semantic Scholar
Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements
Yanjing V. Liu, L. Chai, D. Hiwase, David M. Ross +10 more
2025Blood0 citations
Semantic Scholar
Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)
Victor Ling, P. Marlton, John Reynolds, Mark Dawson +9 more
2025Blood0 citations
Semantic Scholar
AML-743: Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined With Azacitidine in Patients With Newly Diagnosed (ND) or Prior Venetoclax-Exposed Myeloid Malignancies
M. Leahy, Shaun Fleming, Patricia Kropf, C. Chua +16 more
2025Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
POSTER: AML-743 Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined With Azacitidine in Patients With Newly Diagnosed (ND) or Prior Venetoclax-Exposed Myeloid Malignancies
M. Leahy, Shaun Fleming, Patricia Kropf, C. Chua +16 more
2025Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Wei×18
Invite
A. Wei — researcher profile on SciRah
I. Tiong×11
Invite
I. Tiong — researcher profile on SciRah
A. Ivey×8
Invite
A. Ivey — researcher profile on SciRah
G. Garcia-Manero×8
Invite
G. Garcia-Manero — researcher profile on SciRah

×6

Invite

M. Dawson — researcher profile on SciRah

Jacqueline S. Garcia×6

Invite

Jacqueline S. Garcia — researcher profile on SciRah

Meagan A. Jacoby×6

Invite

Meagan A. Jacoby — researcher profile on SciRah

Invite

Ying Zhou — researcher profile on SciRah

Invite

D. Hiwase — researcher profile on SciRah

Chong Chyn Chua×5

Invite

Chong Chyn Chua — researcher profile on SciRah

Invite

S. Fleming — researcher profile on SciRah

Invite

A. Schwarer — researcher profile on SciRah